PT  - JOURNAL ARTICLE
AU  - Yves-Marie Pers
AU  - Marie Godfrin-Valnet
AU  - Joseph Lambert
AU  - Clémentine Fortunet
AU  - Elodie Constant
AU  - Thibault Mura
AU  - Béatrice Pallot-Prades
AU  - Christian Jorgensen
AU  - Jean-Francis Maillefert
AU  - Hubert Marotte
AU  - Daniel Wendling
AU  - Philippe Gaudin
TI  - Response to Tocilizumab in Rheumatoid Arthritis Is Not Influenced by the Body Mass Index of the Patient
AID  - 10.3899/jrheum.140673
DP  - 2015 Apr 01
TA  - The Journal of Rheumatology
PG  - 580--584
VI  - 42
IP  - 4
4099  - http://www.jrheum.org/content/42/4/580.short
4100  - http://www.jrheum.org/content/42/4/580.full
SO  - J Rheumatol2015 Apr 01; 42
AB  - Objective. To assess the relationship between the body mass index (BMI) and the efficacy of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA). Methods. We conducted a retrospective study in 222 patients with RA followed by 5 centers. The European League Against Rheumatism response was evaluated at 6 months. Univariate and multivariate logistic regressions were performed. Results. No significant association between the BMI and the response to TCZ at 6 months was found after adjustment for potential confounding factors (adjusted OR 0.45, 95% CI 0.16–1.24, p = 0.13 and OR 1.19, 95% CI 0.31–4.48, p = 0.78 for BMI 25–30 kg/m2 and BMI > 30 kg/m2, respectively, compared to BMI < 25 kg/m2). Conclusion. Response to TCZ in patients with RA is not influenced by the baseline BMI, in contrast to anti-tumor necrosis factor drugs.